Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.
Arjan Bredenoord, MD
Advertisement
Arjan Bredenoord, MD, gastroenterologist and professor, Amsterdam University Medical Center.
Articles by Arjan Bredenoord, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
The Future of Gene Silencers for ATTR-CM After CARDIO-TTRansform, With Ronald Witteles, MD
2
ESC Congress 2026: Day 2 Recap—6 Headlines to Know
3
STAREE: Statins Reduce Cardiovascular Events But Not Disability in Older Adults
4
Tezepelumab's TSLP Blockade May Address Refractory EoE Gap
5